Search

21. Catastrophic coverage in the Medicare Part D drug benefit: which beneficiaries need it and how much are they spending?

Author(s):

Sen, Aditi P., author
Parasrampuria, Sonal, author
Anderson, Kelly E., author
Anderson, Gerard, author

Publication:

[New York, N.Y.] : The Commonwealth Fund, September 2020

Subject(s):

Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Financing, Personal
United States

22. Capping Medicare beneficiary Part D spending at $2,000: who would it help and how much?

Author(s):

Gangopadhyaya, Anuj, author
Garrett, Bowen, author

Publication:

Washington, DC : Urban Institute, March 2022

Subject(s):

Health Equity -- economics
Health Expenditures -- statistics & numerical data
Health Policy
Medicare Part D -- economics
Prescription Fees -- legislation & jurisprudence
Social Mobility
United States

23. Drug price increases that exceed inflation are costing Medicare Part D billions

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, June 2021

Subject(s):

Drug Costs
Inflation, Economic
Medicare Part D -- economics
Medicare Part D -- trends
Prescription Drugs -- economics
United States

24. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, September 2023

Subject(s):

Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

25. Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act

Author(s):

Sayed, Bisma A., author
Finegold, Kenneth, 1957- author
Olsen, T. Anders, author
Ashok, Kaavya, author
Shutz, Sarah, author
Sheingold, Steven, author
De Lew, Nancy, author
Sommers, Benjamin D., author

Publication:

Washington, D.C. : Assistant Secretary for Planning and Evaluation, Office of Health Policy, July 7, 2023

Subject(s):

Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
State Government
United States
United States.

26. Medicare Part D

Author(s):

Steiner, David J., author

Publication:

[Toronto, Ontario] : Thomson Reuters, 19-December-2022

Subject(s):

Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Drug Costs -- legislation & jurisprudence
United States
Centers for Medicare & Medicaid Services (U.S.)

27. Prices for top Medicare Part D drugs have more than tripled since entering the market

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, August 2023

Subject(s):

Drug Costs -- statistics & numerical data
Drug Costs -- trends
Medicare Part D -- economics
United States

28. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023

Subject(s):

Buprenorphine
Drug Users -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Prescription Drug Diversion -- statistics & numerical data
United States

29. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:

Washington, DC : United States Government Accountability Office, September 19, 2023

Subject(s):

Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Drugs -- economics
United States

30. Projected impacts for Asian Medicare enrollees

Publication:

Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, 2023

Subject(s):

Asian
Drug Costs -- legislation & jurisprudence
Forecasting
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States
United States.